Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© The Royal Society of Chemistry 2021. In this chapter, we discuss the rise and rationale for public-private partnerships (PPP) in phenotypic drug discovery (PDD) from both the academic and industrial perspectives. We then give a review of the three most common "precompetitive"PPP in PDD formats, namely collaborative, co-localized and industry-supported, before finally providing an outlook/conclusion, highlighting the factors we feel contribute to successful PDD partnerships, and the directions we feel these partnerships could take to improve outcomes for both partners.

Original publication

DOI

10.1039/9781839160721-00118

Type

Chapter

Book title

RSC Drug Discovery Series

Publication Date

01/01/2021

Volume

2021-January

Pages

118 - 139